Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (37): 6921-6925.doi: 10.3969/j.issn.2095-4344.2012.37.017

Previous Articles     Next Articles

Influence of different concentrations of monosodium urate on inflammatory factors in synoviocytes in vitro

Sun Gui-cai1, Xu Yi-er2, Yu Xue-feng1, Wu Hong-liang1, Ling Xiao-peng1   

  1. 1Department of Orthopedics, Fourth Affiliated Hospital of Nanchang University, Nanchang 330003, Jiangxi Province, China
    2Graduate School of Heilongjiang University of Traditional Chinese Medicine, Harbin 150040, Heilongjiang Province, China
  • Received:2012-01-12 Revised:2012-02-23 Online:2012-09-09 Published:2012-09-09
  • About author:Sun Gui-cai☆, Doctor, Associate chief physician, Department of Orthopedics, Fourth Affiliated Hospital of Nanchang University, Nanchang 330003, Jiangxi Province, China xulei010207@126.com

PDF

552

Abstract:

BACKGROUND: Monosodium urate stimulates synoviocytes to prepare an in vitro model of acute gouty arthritis, which is important in evaluating of action mechanisms of this kind of drugs.
OBJECTIVE: To discuss the influential factors of establishing a model of acute gouty arthritis by directly stimulating synoviocytes in vitro with different concentrations of monosodium urate and observing concentration changes of cytokine.
METHODS: Synoviocytes from rats were treated with 0 (control group), 50, 125, 250, 500, 1 000 μmol/L monosodium urate. At 24 and 48 hours, cell viability and levels of interleukin-1 beta, interleukin-8, and tumor necrosis factor alpha in culture medium were detected.
RESULTS AND CONCLUSION: There were no effects on cell viability within 24 and 48 hours in control group and treatment groups. Compared with the control group, levels of interleukin-1 beta, interleukin-8, and tumor necrosis factor alpha in the medium of treatment groups were all increased, while the highest concentration was found when drug concentration was 500 μm/L and dosing interval was 24 hours. Monosodium urate at a certain concentration and dosing interval contributes to the screening of ideal models of acute gouty arthritis.

CLC Number: